Rule 2.7, 3.10.3, 3.10.4, 3.10.5

### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity Sundance Resources Limited ABN 19 055 719 394 We (the entity) give ASX the following information. Part 1 - All issues You must complete the relevant sections (attach sheets if there is not enough space). 1 \*Class of \*securities issued or to Fully paid ordinary shares be issued 2 187,500,000 Number of \*securities issued or to be issued (if known) or maximum number which may be issued 3 Fully paid ordinary shares Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

<sup>+</sup> See chapter 19 for defined terms.

4 Yes, the shares will rank equally in all Do the \*securities rank equally respects with fully paid ordinary shares in all respects from the +issue date with an existing +class of quoted \*securities? If the additional \*securities do not rank equally, please state: • the date from which they do the extent to which they participate for the next dividend. (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution interest payment 5 Issue price or consideration \$0.004 per share 6 Purpose of the issue To advance the Mbalam-Nabeba Iron Ore (If issued as consideration for Project and for general working capital the acquisition of assets, clearly identify those assets) 6a Is the entity an \*eligible entity Yes that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b -6h in relation to the \*securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder 29 November 2017 resolution under rule 7.1A was passed 6c 187,500,000 Number of \*securities issued without security holder approval under rule 7.1 6d Number of \*securities issued N/A with security holder approval under rule 7.1A

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
C.f		NI/A	
6f	Number of *securities issued under an exception in rule 7.2	N/A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	7.1 – 1,031,377,043 7.1A – 812,584,695	
7	<sup>+</sup> Issue dates	6 August 2018	
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.		
	Cross reference: item 33 of Appendix 3B.		
			L.a.
•		Number	*Class
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	8,313,346,952	Fully paid ordinary shares

<sup>+</sup> See chapter 19 for defined terms.

9 Number and \*class of all \*securities not quoted on ASX (*including* the \*securities in section 2 if applicable)

Number	⁺Class
260,000,000	Unquoted Investor Consortium Options exercisable at \$0.0695 per share
200,000,000	Unquoted Noble Options exercisable at \$0.0695 per option
260,000,000	Unquoted Wafin Options exercisable at \$0.0695 per option
100,000,000	Unquoted 2017 Options exercisable at \$0.003 per option expiring 7 April 2022
100,000,000	Unquoted 2017 Options exercisable at \$0.006 per option vesting 1 December 2018 and expiring on 7 April 2023
Total unquoted	expiring on 7 April 2023
options: 920,000,000	
200,000	Noble Convertible Notes
240,000	Investor Consortium Convertible Notes
400,000	Wafin Convertible Notes
70,000	2015 Investor Group Convertible Notes
2,600	2016 Investor Group Convertible Notes
Total Convertible Notes: 912,600	

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A			

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	*Class of *securities to which the offer relates	N/A
15	*Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.	N/A
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
0.4		
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements in full through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	*Issue date	N/A

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

	3 - Quotation of securities ed only complete this section if you are applying for quotation of securities			
34	Type of <sup>+</sup> securities (tick one)			
(a)	*Securities described in Part 1			
(b)		Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible		
Entiti	ies that have ticked box 34(a)			
Additio	onal securities forming a new class of securities			
Tick to docume	o indicate you are providing the information or nents			
35	If the *securities are *equity securities, the names of the 20 largest hol the additional *securities, and the number and percentage of ad *securities held by those holders			
36	If the *securities are *equity securities, a distribution schedule of the ad *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over	1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000		
37	A copy of any trust deed for the additional *securities			
Entiti	ies that have ticked box 34(b)			
38	Number of *securities for which *quotation is sought			
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought			

<sup>+</sup> See chapter 19 for defined terms.

40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	<sup>+</sup> Class
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)		

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 6 August 2018

(Company secretary)

Print name: CAROL MARINKOVICH

== == == ==

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B - Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
<i>Insert</i> number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	7,102,023,617	
<ul> <li>Add the following:         <ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period with shareholder approval</li> </ul> </li> <li>Number of partly paid <sup>+</sup>ordinary securities that became fully paid in that 12 month period         <ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of</li> </ul> </li> </ul>	Issued under Listing Rule 7.2  11 August 2017 – 384,133  25 August 2017 – 3,174,715  7 September 2017 – 42,610,469  7 September 2017 – 5,400  25 September 2017 – 386,044,838  4 December 2017 – 147,345,679  13 February 2018 – 185,714,286  26 February 2018 – 111,428,571  26 June 2018 – 55,000,000  Issued under Listing Rule 7.4  25 September 2017 – 92,115,144 (ratified 29 November 2017)  Shares issued under Cleansing Prospectus  11 April 2018 - 100	
securities on different dates as separate line items  Subtract the number of fully paid  +ordinary securities cancelled during that  12 month period	-	
"A"	8,125,846,952	

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
<b>Multiply</b> "A" by 0.15	1,218,877,043
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule
<b>Insert</b> number of *equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	• 6 August 2018 – 187,500,000
<ul> <li>Under an exception in rule 7.2</li> </ul>	
• Under rule 7.1A	
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>	
<ul> <li>Note:         <ul> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> </ul>	
"C"	187,500,000
Step 4: Subtract "C" from ["A" x ' placement capacity under rule 7.1	-
"A" x 0.15	1,218,877,043
Note: number must be same as shown in Step 2	
Subtract "C"	187,500,000
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	1,031,377,043
	[Note: this is the remaining placement capacity under rule 7.1]

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Tale 7:1A – Additional placem	ent capacity for eligible entities	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"  Note: number must be same as shown in	8,125,846,952	
Step 1 of Part 1  Step 2: Calculate 10% of "A"		
"D"	0.10  Note: this value cannot be changed	
Multiply "A" by 0.10	812,584,695	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	N/A	
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix</li> </ul>		
<ul> <li>3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10  Note: number must be same as shown in Step 2	812,584,695	
Subtract "E"  Note: number must be same as shown in Step 3	0	
<b>Total</b> ["A" x 0.10] – "E"	812,584,695  Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.